MedTrace Logo

Triple Therapy for Intermediate-advanced HCC With BDTT (TALENP002)

NCT06602011 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2024-10-15

No results posted yet for this study

Summary

This is a multicenter, Single-arm, Real-world Study to evaluate the efficacy and safety of Transcatheter arterial chemoembolization (TACE), Lenvatinib combined with Tislelizumab (Triple Therapy) for patients with Hepatocellular Carcinoma (HCC) with bile duct tumor thrombus (BDTT).

Conditions

Interventions

COMBINATION_PRODUCT

TACE, Lenvatinib, combined with Tislelizumab group

TACE, Lenvatinib \[8mg(\<60kg)/12mg(\>60kg) orally daily\] combination with Tislelizumab (200mg administered intravenous injection on Day 1 of each 21-day cycle). After the triple therapy, surgical resection is an option if assessed by the investigator to be feasible, or continued until disease progression or intolerable if not.

Sponsors & Collaborators

  • Fujian Provincial Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-30
Primary Completion
2027-07-01
Completion
2028-10-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06602011 on ClinicalTrials.gov